Cargando…

Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction

A bispecific antibody (bsAb) is a class of engineered antibody molecules that simultaneously binds to two different antigens by having two kinds of antigen-binding domains. One of the major obstacles for the bsAb production is the incorrect chain-pairing problem, wherein each heavy and light chain s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Risa, Nakahara, Ishin, Kumagai, Izumi, Asano, Ryutaro, Nakanishi, Takeshi, Makabe, Koki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520027/
https://www.ncbi.nlm.nih.gov/pubmed/37749185
http://dx.doi.org/10.1038/s41598-023-43110-0
_version_ 1785109821405528064
author Yamada, Risa
Nakahara, Ishin
Kumagai, Izumi
Asano, Ryutaro
Nakanishi, Takeshi
Makabe, Koki
author_facet Yamada, Risa
Nakahara, Ishin
Kumagai, Izumi
Asano, Ryutaro
Nakanishi, Takeshi
Makabe, Koki
author_sort Yamada, Risa
collection PubMed
description A bispecific antibody (bsAb) is a class of engineered antibody molecules that simultaneously binds to two different antigens by having two kinds of antigen-binding domains. One of the major obstacles for the bsAb production is the incorrect chain-pairing problem, wherein each heavy and light chain should form pairings with the correct counterpart’s chains, but the structural similarity of the incorrect partners also forms the incorrect pairings. This study aimed to demonstrate a bsAb construction method using intein-mediated protein trans-splicing to create IgG–Fab(2)–type bsAbs, which is a modified antibody with a structure in which two additional Fabs are linked to the N-terminus of the heavy chain of an IgG molecule. The chain-paring problem between a heavy chain and a light chain is circumvented by separate expression and purification of the IgG part and the Fab part. We found that the deletion of a possible glycosylation residue improved the reaction yield and side-reaction cleavage in the protein ligation step. The resulting bsAb, IgG–Fab(2) (Her2/CD3), demonstrated target binding activity and cytotoxicity mediated by activated T cells. These results indicate that the use of the protein ligation to produce the IgG–Fab(2) type bsAb will expand the bsAb production method.
format Online
Article
Text
id pubmed-10520027
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105200272023-09-27 Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction Yamada, Risa Nakahara, Ishin Kumagai, Izumi Asano, Ryutaro Nakanishi, Takeshi Makabe, Koki Sci Rep Article A bispecific antibody (bsAb) is a class of engineered antibody molecules that simultaneously binds to two different antigens by having two kinds of antigen-binding domains. One of the major obstacles for the bsAb production is the incorrect chain-pairing problem, wherein each heavy and light chain should form pairings with the correct counterpart’s chains, but the structural similarity of the incorrect partners also forms the incorrect pairings. This study aimed to demonstrate a bsAb construction method using intein-mediated protein trans-splicing to create IgG–Fab(2)–type bsAbs, which is a modified antibody with a structure in which two additional Fabs are linked to the N-terminus of the heavy chain of an IgG molecule. The chain-paring problem between a heavy chain and a light chain is circumvented by separate expression and purification of the IgG part and the Fab part. We found that the deletion of a possible glycosylation residue improved the reaction yield and side-reaction cleavage in the protein ligation step. The resulting bsAb, IgG–Fab(2) (Her2/CD3), demonstrated target binding activity and cytotoxicity mediated by activated T cells. These results indicate that the use of the protein ligation to produce the IgG–Fab(2) type bsAb will expand the bsAb production method. Nature Publishing Group UK 2023-09-25 /pmc/articles/PMC10520027/ /pubmed/37749185 http://dx.doi.org/10.1038/s41598-023-43110-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yamada, Risa
Nakahara, Ishin
Kumagai, Izumi
Asano, Ryutaro
Nakanishi, Takeshi
Makabe, Koki
Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title_full Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title_fullStr Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title_full_unstemmed Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title_short Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
title_sort construction of igg–fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520027/
https://www.ncbi.nlm.nih.gov/pubmed/37749185
http://dx.doi.org/10.1038/s41598-023-43110-0
work_keys_str_mv AT yamadarisa constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction
AT nakaharaishin constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction
AT kumagaiizumi constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction
AT asanoryutaro constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction
AT nakanishitakeshi constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction
AT makabekoki constructionofiggfab2bispecificantibodyviainteinmediatedproteintranssplicingreaction